Vanassche Thomas, Engelen Matthias M, Orlando Christelle, Vandenbosch Kristel, Gadisseur Alain, Hermans Cedric, Jochmans Kristin, Minon Jean-Marc, Motte Serge, Peperstraete Harlinde, Péters Pierre, Sprynger Muriel, Lancellotti Patrizio, Dehaene Isabelle, Emonts Patrick, Vandenbriele Christophe, Verhamme Peter, Oury Cecile
Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Department of Haematology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel, Brussels, Belgium.
Acta Clin Belg. 2023 Dec;78(6):497-508. doi: 10.1080/17843286.2023.2241692. Epub 2023 Aug 7.
COVID-19 is associated with an increased risk for thrombotic complications. The trials investigating the optimal thromboprophylactic dose are performed in challenging times and seemingly produce conflicting evidence. The burdensome circumstances, divergent endpoints, and different analytical approaches hamper comparison and extrapolation of available evidence. Most importantly, clinicians should provide thromboprophylaxis in hospitalized COVID-19 patients while (re)assessing bleeding and thrombotic risk frequently. The COVID-19 Thromboprophylaxis Working Group of the BSTH updated its guidance document. It aims to summarize the available evidence critically and to guide clinicians in providing the best possible thromboprophylaxis.
新型冠状病毒肺炎（COVID-19）与血栓形成并发症风险增加相关。在充满挑战的时期开展了调查最佳血栓预防剂量的试验，且这些试验似乎产生了相互矛盾的证据。繁重的情况、不同的终点以及不同的分析方法妨碍了对现有证据的比较和推断。最重要的是，临床医生应在住院的COVID-19患者中进行血栓预防，同时频繁（重新）评估出血和血栓形成风险。英国血液学标准委员会（BSTH）的COVID-19血栓预防工作组更新了其指导文件。其目的是批判性地总结现有证据，并指导临床医生提供尽可能最佳的血栓预防措施。
